Phase 3 N=310 Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
Pulmonary Hypertension
Primary: 6-minute Walk Distance (6MWD) — 370; 365; 15; 11 meters — p=0.089
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=416 RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
Metastatic Renal Cell Carcinoma
Primary: Progressive Free Survival (PFS) in Patients Who Receive RAD001 Plus Best Supportive Care(BSC) Versus Patients Who Receive Matching Placebo Plus BSC — 4.90; 1.87 Months
Phase 4 N=12 Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion
Healthy · Type 2 Diabetes
Primary: Glucagon-like Peptide-1 Secretion After Meal Ingestion — 0.82; 1.24 nmol/l/min
Phase 2 N=20 Pilot Study of Open-label Placebo to Treat Major Depressive Disorder
Major Depressive Disorder
Primary: Feasibility — 33 screens
Phase 2 N=94 Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 17 percentage of participants
Phase 2 N=21 Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Glioblastoma · Gliosarcoma
Primary: Progression-free Survival at 6 Months — 61.9 percentage of participants
Phase 2 N=90 Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
Colorectal Cancer
Primary: Major Morbidity Related to the Intact Primary Tumor — 16.3 probability of major morbidity (%)
Phase 1 N=27 Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Non-Small Cell Lung Cancer
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1) — 2; 3 participants
Phase 4 N=473 An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis
Osteoarthritis
Primary: Change From Baseline in Visual Analogue Scale for Pain (VAS-pain) Score at Week 2 — 71.86; 68.03; -29.721; -21.972 mm — p=<0.05
Phase 3 N=2,235 Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly
Influenza
Primary: Number of Subjects Reporting Solicited Adverse Events After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine — 78; 73; 47; 51 Participants
Phase 3 N=611 A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3 — 59.75; 65.70; 26.67 percentage of participants — p=<0.0001
N/A N=27 Novel Non-Invasive Monitoring Parameter in Healthy Volunteers
No Conditions · Focus is Respiratory Rate
Primary: The Covidien Nellcor Respiration Rate Software Shall Determine Respiration Rate Measured as Mean and Standard Deviation With Accuracy That is Non-inferior to Predicate…
Phase 2 N=16 AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
Ovarian Neoplasms
Primary: Percentage of Participants With a Repeat Paracentesis Response (RPR) — 62.5 percentage of participants
Phase 3 N=399 Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3 — 41.67; 48.12; 24.43 percentage of participants — p=<0.0001
N/A N=63 Novel Non-Invasive Monitoring Parameter in a Hospital Setting
Respiratory Insufficiency · Respiratory Failure
Primary: The Covidien Nellcor Respiration Rate Software Shall Determine Respiration Rate Measured as Mean and Standard Deviation With Accuracy That is Non-inferior to Predicate…